TY - JOUR
T1 - Illustrated State-of-the-Art Capsules of the ISTH 2021 Congress
AU - Krishnaswamy, Sriram
AU - Ageno, Walter
AU - Arabi, Yaseen
AU - Barbui, Tiziano
AU - Cannegieter, Suzanne
AU - Carrier, Marc
AU - Cleuren, Audrey C
AU - Collins, Peter
AU - Panicot-Dubois, Laurence
AU - Freedman, Jane E
AU - Freson, Kathleen
AU - Hogg, Philip
AU - James, Andra H
AU - Kretz, Colin A
AU - Lavin, Michelle
AU - Leebeek, Frank W G
AU - Li, Weikai
AU - Maas, Coen
AU - Machlus, Kellie
AU - Makris, Michael
AU - Martinelli, Ida
AU - Medved, Leonid
AU - Neerman-Arbez, Marguerite
AU - O'Donnell, James S
AU - O'Sullivan, Jamie
AU - Rajpurkar, Madhvi
AU - Schroeder, Verena
AU - Spiegel, Paul Clinton
AU - Stanworth, Simon J
AU - Green, Laura
AU - Undas, Anetta
N1 - Funding Information:
WA has received grant funding from Bayer and payments from Bayer, Portola, Aspen, Sanofi, BMS/Pfizer, Daiichi Sankyo; MC has received grant funding from Leo Pharma, Pfizer, BMS and consulting fees from Leo Pharma, Pfizer, Bayer, BMS, Servier, Sanofi; ACC has received funding from the American Heart Association; PC has received grant funding from CSL Behring, Werfen (TEM International), Haemonectics, the Welsh Government and personal fees from CSL Behring, Werfen; JEF has received funding from the American Heart Association; KF has received funding from Sobi (Swedish Orphan Biovitrum); ML has received consulting fees from Sobi, Tremeau Pharmaceuticals, Takeda; FWGL has received grant funding from CSL Behring, Takeda/Baxalta, uniQure, SOBI and consulting fees from CSL Behring, Biomarin, Takeda, UniQure; KM has received funding from the American Society of Hematology, NIH and consulting fees from STRM.BIO; MM has received grants from Bayer, BPL, CSL Behring, Kedrion, NovoNordisk, Octapharma, Pfizer, Roche, Sobi, Takeda and consulting fees from Novo Nordisk, Grifols, Sanofi; LM has received funding from the NIH; JO has received grant funding from LEO Pharma; VS has received funding from the Swiss National Science Foundation; all other authors declare no conflicts of interest.
Publisher Copyright:
© 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
PY - 2021/7
Y1 - 2021/7
N2 - This year's Congress of the International Society of Thrombosis and Haemostasis (ISTH) was hosted virtually from Philadelphia July 17-21, 2021. The conference, now held annually, highlighted cutting-edge advances in basic, population and clinical sciences of relevance to the Society. Despite being held virtually, the 2021 congress was of the same scope and quality as an annual meeting held in person. An added feature of the program is that talks streamed at the designated times will then be available on-line for asynchronous viewing. The program included 77 State of the Art (SOA) talks, thematically grouped in 28 sessions, given by internationally recognized leaders in the field. The SOA speakers were invited to prepare brief illustrated reviews of their talks that were peer reviewed and are included in this article. The topics, across the main scientific themes of the congress, include Arterial Thromboembolism, Coagulation and Natural Anticoagulants, COVID-19 and Coagulation, Diagnostics and Omics, Fibrinogen, Fibrinolysis and Proteolysis, Hemophilia and Rare Bleeding Disorders, Hemostasis in Cancer, Inflammation and Immunity, Pediatrics, Platelet Disorders, von Willebrand Disease and Thrombotic Angiopathies, Platelets and Megakaryocytes, Vascular Biology, Venous Thromboembolism and Women's Health. These illustrated capsules highlight the major scientific advances with potential to impact clinical practice. Readers are invited to take advantage of the excellent educational resource provided by these illustrated capsules. They are also encouraged to use the image in social media to draw attention to the high quality and impact of the science presented at the congress.
AB - This year's Congress of the International Society of Thrombosis and Haemostasis (ISTH) was hosted virtually from Philadelphia July 17-21, 2021. The conference, now held annually, highlighted cutting-edge advances in basic, population and clinical sciences of relevance to the Society. Despite being held virtually, the 2021 congress was of the same scope and quality as an annual meeting held in person. An added feature of the program is that talks streamed at the designated times will then be available on-line for asynchronous viewing. The program included 77 State of the Art (SOA) talks, thematically grouped in 28 sessions, given by internationally recognized leaders in the field. The SOA speakers were invited to prepare brief illustrated reviews of their talks that were peer reviewed and are included in this article. The topics, across the main scientific themes of the congress, include Arterial Thromboembolism, Coagulation and Natural Anticoagulants, COVID-19 and Coagulation, Diagnostics and Omics, Fibrinogen, Fibrinolysis and Proteolysis, Hemophilia and Rare Bleeding Disorders, Hemostasis in Cancer, Inflammation and Immunity, Pediatrics, Platelet Disorders, von Willebrand Disease and Thrombotic Angiopathies, Platelets and Megakaryocytes, Vascular Biology, Venous Thromboembolism and Women's Health. These illustrated capsules highlight the major scientific advances with potential to impact clinical practice. Readers are invited to take advantage of the excellent educational resource provided by these illustrated capsules. They are also encouraged to use the image in social media to draw attention to the high quality and impact of the science presented at the congress.
UR - http://www.scopus.com/inward/record.url?scp=85112390420&partnerID=8YFLogxK
U2 - 10.1002/rth2.12532
DO - 10.1002/rth2.12532
M3 - Review article
C2 - 34296056
SN - 2475-0379
VL - 5
SP - 1
EP - 34
JO - Research and practice in thrombosis and haemostasis
JF - Research and practice in thrombosis and haemostasis
IS - 5
M1 - e12532
ER -